Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by Swiss National Bank

Swiss National Bank boosted its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 94.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 79,100 shares of the company's stock after purchasing an additional 38,400 shares during the period. Swiss National Bank owned 0.15% of Janux Therapeutics worth $4,235,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in the company. Avanza Fonder AB acquired a new stake in Janux Therapeutics during the fourth quarter worth about $139,000. Chicago Capital LLC bought a new stake in Janux Therapeutics in the fourth quarter worth approximately $230,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Janux Therapeutics in the 3rd quarter valued at about $317,000. Virtu Financial LLC increased its stake in Janux Therapeutics by 48.0% during the 3rd quarter. Virtu Financial LLC now owns 7,463 shares of the company's stock valued at $339,000 after purchasing an additional 2,419 shares in the last quarter. Finally, Legato Capital Management LLC purchased a new stake in Janux Therapeutics in the 4th quarter valued at $347,000. Institutional investors and hedge funds own 75.39% of the company's stock.

Janux Therapeutics Price Performance

JANX stock traded down $0.68 during mid-day trading on Friday, reaching $29.10. 469,177 shares of the company's stock were exchanged, compared to its average volume of 841,429. The company has a market cap of $1.72 billion, a price-to-earnings ratio of -24.87 and a beta of 3.23. Janux Therapeutics, Inc. has a 12-month low of $28.91 and a 12-month high of $71.71. The stock's 50 day moving average is $35.60 and its 200 day moving average is $45.99.

Remove Ads

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, research analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Analyst Ratings Changes

JANX has been the subject of several analyst reports. William Blair restated an "outperform" rating on shares of Janux Therapeutics in a research note on Friday, January 10th. Leerink Partners upped their target price on Janux Therapeutics from $79.00 to $91.00 and gave the company an "outperform" rating in a report on Tuesday, December 3rd. Lifesci Capital upgraded shares of Janux Therapeutics to a "strong-buy" rating in a research note on Friday, December 27th. BTIG Research boosted their price objective on shares of Janux Therapeutics from $82.00 to $100.00 and gave the stock a "buy" rating in a report on Tuesday, December 3rd. Finally, Stifel Nicolaus upped their price objective on Janux Therapeutics from $70.00 to $115.00 and gave the company a "buy" rating in a research report on Tuesday, December 3rd. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, Janux Therapeutics has a consensus rating of "Buy" and a consensus target price of $92.44.

Insider Buying and Selling

In related news, insider Andrew Hollman Meyer sold 13,334 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $54.88, for a total transaction of $731,769.92. Following the completion of the transaction, the insider now directly owns 82,139 shares of the company's stock, valued at $4,507,788.32. This represents a 13.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Ra Capital Management, L.P. bought 110,206 shares of the business's stock in a transaction dated Friday, March 7th. The shares were acquired at an average cost of $31.02 per share, with a total value of $3,418,590.12. Following the completion of the purchase, the director now owns 10,141,287 shares in the company, valued at approximately $314,582,722.74. This represents a 1.10 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 25,002 shares of company stock worth $1,279,953. Company insiders own 29.40% of the company's stock.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.